Saturday 17 October 2026 Export VIR’s income statement to Excel — free account

Vir Biotechnology, Inc.

Vir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024. In the quarter to June 2026, revenue grew 19,582.5%, EPS grew 160.0% and free cash flow grew 200.5%, each against the same quarter a year earlier. Dividend growth for three consecutive years.

9.96 0.51 −4.87%

Follow VIR

Alert me

Market cap: $1.8B
P/E: 0.0×
Fwd P/E: −5.9×
Dividend yield: —
F-score: 4/9
Altman Z: −0.57
Beneish M: n/a
Dividend safety: n/a

Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 8.29

Totals in millions of $.

	Dec 25			Mar 26			Jun 26			Sep 26
Buy	—	—	—	—	—	—	—	—	—	—	—	—
Sell	6	2	1	13	2	2	1	2	—	—	—	—

Insider Ownership 20.06%

Capital & Financial Ratios $m

Market Cap 1,770.00

Revenue 303.23

Net Income (251.68)

Free Cash Flow (203.67)

Net Debt (534.65)

Current Ratio 6.04

Debt/Equity 0.00

P/E ratio 0.00

Fwd P/E (5.87)

P/S ratio 5.51

P/B ratio 1.70

Past 5Y EPS Growth —

This Y EPS Growth 43.95%

Next Y EPS Growth (43.86%)

Next Y revenue growth 257.66%

Next 5Y EPS Growth 12.69%

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years

P/S against its own 10 years 22.58%

10-year low 10-year high

P/B against its own 10 years 58.08%

10-year low 10-year high

EV/Sales against its own 10 years 43.88%

10-year low 10-year high

Dividends

Payout Ratio —

Annual Dividend Rate —

Annual Dividend Yield —

	total	individual payouts
2025	Powerpack
2024	Powerpack
2023	Powerpack
2022	Powerpack
2021	Powerpack
2020	Powerpack
2019	Powerpack

predictions special payouts not included in total or ratios

Assets vs Liabilities $m

	2023	2024	2025	Q'26
Cash	1,536	995	469	535
Receivables	—	—	—	—
Inventory	—	—	—	—
Other	—	—	—	—
	1,588	1,042	514	574

	2023	2024	2025	Q'26
Payables	6	5	10	18
ST’ Debt	—	—	—	—
Other	—	16	—	—
	175	120	93	95

Compound Annual Growth %

	10y	5y	3y
Sales	—	(2.14%)	(65.12%)
Cash Flow	—	0.00%	0.00%
Earnings	—	0.00%	0.00%
Book Value	—	1.32%	(28.32%)

Revenue $m

	Mar	Jun	Sep	Dec	Year
’26	0	239	—	—	—
’25	3	1	0	64	69
’24	56	3	2	12	74
’23	63	4	3	17	86
’22	1,232	(41)	375	49	1,616
’21	2	177	104	813	1,095
’20	6	67	2	2	76

Fiscal quarters ending in the months shown.

Operating Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(132)	123	—	—	—
’25	(78)	(120)	(168)	(26)	(392)
’24	(109)	(78)	(171)	(88)	(446)
’23	(126)	(389)	(156)	(108)	(779)
’22	550	960	118	35	1,663
’21	(90)	140	(106)	8	(48)
’20	(48)	(11)	(50)	(82)	(191)

Fiscal quarters ending in the months shown.

Free Cash Flow $m

	Mar	Jun	Sep	Dec	Year
’26	(133)	123	—	—	—
’25	(79)	(123)	(168)	(26)	(396)
’24	(111)	(78)	(174)	(87)	(450)
’23	(133)	(399)	(160)	(109)	(800)
’22	534	940	99	23	1,595
’21	(90)	138	(112)	(5)	(69)
’20	(50)	(12)	(51)	(84)	(197)

Fiscal quarters ending in the months shown.

EPS $

	Mar	Jun	Sep	Dec	Year
’26	(0.85)	0.47	—	—	—
’25	(0.88)	(0.80)	(1.17)	(0.31)	(3.16)
’24	(0.48)	(1.02)	(1.56)	(0.76)	(3.83)
’23	(1.06)	(1.45)	(1.22)	(0.86)	(4.59)
’22	3.85	(0.58)	1.30	(0.76)	3.83
’21	(1.32)	0.46	0.82	3.92	3.96
’20	(0.71)	(0.27)	(0.67)	(0.83)	(2.51)

Fiscal quarters ending in the months shown.

Group	Line	2016	2017	2018	2019	2020	2021	2022	2023	2024	2025	2026e
Price, $
Price, $	Low	—	—	—	11.65	12.00	25.31	18.05	7.72	6.56	4.16	Analyst estimates 2026–2028 Powerpack
	High	—	—	—	16.50	75.00	141.01	41.85	31.55	13.09	14.45
People
People	Employees	—	—	—	229	327	444	576	587	408	367
	Revenue/emp, $m	—	0.00	0.00	0.04	0.23	2.47	2.81	0.15	0.18	0.19
Income, $m
Income, $m	Revenue	—	3	11	8	76	1,095	1,616	86	74	69
	Gross margin, %	—	100.00	100.00	100.00	100.00	93.99	90.94	96.79	98.86	99.96
	EBT	—	(81)	(116)	(175)	(299)	550	754	(628)	(523)	(438)
	EBT margin, %	—	(2,982.87)	(1,090.78)	(2,157.08)	(391.02)	50.19	46.68	(728.93)	(704.95)	(638.56)
	Net income	—	(70)	(116)	(175)	(299)	529	516	(615)	(522)	(438)
	Depreciation	—	0	2	4	8	6	(2)	11	20	21
Per share, $
Per share, $	Revenue	—	1.26	1.39	0.27	0.64	8.43	12.18	0.64	0.54	0.49
	Earnings	—	(32.46)	(15.12)	(5.76)	(2.51)	4.07	3.89	(4.59)	(3.83)	(3.16)
	Cash flow	—	(30.85)	(12.27)	(4.27)	(1.60)	(0.37)	12.54	(5.81)	(3.28)	(2.83)
	Capex	—	(1.27)	(1.07)	(0.29)	(0.05)	(0.17)	(0.51)	(0.16)	(0.03)	(0.03)
	Free cash flow	—	(32.12)	(13.34)	(4.57)	(1.66)	(0.53)	12.03	(5.97)	(3.30)	(2.86)
	Book value	—	0.00	(23.37)	13.97	6.02	11.02	15.67	11.86	8.44	5.52
	Shares, m	—	2	8	30	119	130	133	134	136	139
Valuation, ×
Valuation, ×	P/E	—	0.00	0.00	0.00	0.00	10.42	6.37	0.00	0.00	0.00
	P/S	—	0.00	14.73	47.19	41.79	4.96	2.05	16.36	13.48	12.18
	P/B	—	0.00	0.00	0.90	4.45	3.80	1.59	0.89	0.87	1.09
	EV/Sales	—	0.00	(18.19)	(0.97)	32.03	4.31	0.55	(1.46)	0.07	5.34
	EV/FCF	—	0.00	1.39	0.06	(12.40)	(68.03)	0.56	0.16	(0.01)	(0.92)
Cash, $m
Cash, $m	Operating cash flow	—	(66)	(94)	(130)	(191)	(48)	1,663	(779)	(446)	(392)
	Capex	—	(3)	(8)	(9)	(6)	(22)	(68)	(22)	(4)	(5)
	Free cash flow	—	(69)	(102)	(139)	(197)	(69)	1,595	(800)	(450)	(396)
Balance, $m
Balance, $m	Working capital	—	180	78	344	673	1,222	2,008	1,413	923	421
	Total debt	—	—	—	1	71	138	128	—	—	—
	Net debt	—	(188)	(109)	(390)	(745)	(717)	(2,415)	(1,536)	(995)	(469)
	Shareholders’ equity	—	—	(179)	424	717	1,432	2,078	1,590	1,150	765
Returns, %
Returns, %	ROA	—	(31.46)	(120.97)	(49.65)	(41.75)	36.80	21.69	(26.06)	(31.46)	(36.47)
	ROIC	—	0.00	0.00	(324.07)	0.00	36.77	0.00	(783.90)	(235.77)	(101.09)
	ROE	—	56.33	93.39	(142.74)	(52.36)	49.20	29.39	(33.53)	(38.09)	(45.73)

Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Company	Market cap	P/E	Fwd P/E	Revenue growth (Q)	EPS growth (Q)	FCF growth (Q)	Gross margin (Q)	EBIT margin (Q)	Compare
MRVI Maravai LifeSciences Holdings, Inc.	$1.8B	— (loss-making)	— (loss-making)	+8.53% (above 0%: growing)	n/m	+127.57% (above 0%: growing)	40.14%	(29.33%)	Compare
PVLA Palvella Therapeutics, Inc.	$1.8B	— (loss-making)	— (loss-making)	−99.09% (below 0%: shrinking)	n/m	−136.38% (below 0%: shrinking)	100.00%	0.00%	Compare
MESO Mesoblast Limited	$1.8B	— (loss-making)	—	−13.41% (below 0%: shrinking)	n/m	−89.23% (below 0%: shrinking)	(353.35%)	(909.40%)	Compare
URGN Urogen Pharma	$1.8B	— (loss-making)	— (loss-making)	+199.22% (above 0%: growing)	n/m	+17.26% (above 0%: growing)	90.93%	0.15%	Compare
XNCR Xencor, Inc.	$1.8B	— (loss-making)	— (loss-making)	+17.46% (above 0%: growing)	n/m	−52.91% (below 0%: shrinking)	100.00%	(72.37%)	Compare
VIR Vir Biotechnology, Inc.	$1.8B	— (loss-making)	— (loss-making)	+19,582.54% (above 0%: growing)	n/m	+200.47% (above 0%: growing)	100.00%	30.75%
SEPN Septerna, Inc.	$1.8B	— (loss-making)	— (loss-making)	+22,375.63% (above 0%: growing)	n/m	−9.01% (below 0%: shrinking)	100.00%	(62.95%)	Compare
BHVN Biohaven Ltd.	$1.7B	— (loss-making)	— (loss-making)	+131.43% (above 0%: growing)	n/m	+49.13% (above 0%: growing)	0.00%	0.00%	Compare
TRVI Trevi Therapeutics, Inc.	$1.7B	— (loss-making)	—	—	n/m	−73.77% (below 0%: shrinking)	0.00%	0.00%	Compare
Median of peers	$1.8B	—	—	+17.46%	—	−30.96%	65.54%	(14.66%)

All 614 Biotechnology stocks →

Vir Biotechnology, Inc. (VIR) key facts

Concern: Vir Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $68.6 million, down 7.61% from fiscal 2024.
Concern: Vir Biotechnology, Inc. reported a net loss of $438.0 million, or a loss of $3.16 per share, for fiscal 2025.
Vir Biotechnology, Inc. (VIR) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
As of October 16, 2026, VIR traded at $9.96, a market capitalization of $1.8 billion.
Trailing earnings are negative, so a P/E ratio is not meaningful; the stock trades at 5.5× sales.
Return on equity was −45.7% and debt-to-equity 0.00.
Its Piotroski F-score is 4 out of 9 and its Altman Z-score is −0.57 (distress zone) for fiscal 2025.